Kadimastem Ltd.
Industry
- Pharmaceuticals
- Biotechnology
- Gene Therapy, Cell Therapy
- Drug Discovery Technologies
See more in Biomedtracker
Latest on Kadimastem Ltd.
In Vivo
• By David Wild
Neurological disorders account for roughly 45% of rare diseases; and 85% of rare and ultra-rare disease trace back to a single gene defect. Given this, the potential for regenerative therapies to bene
Scrip
• By Deanna Kamienski
Financings In the second quarter of 2013, start-up companies brought in an impressive $907.2 million, 56% more than the previous quarter and the largest amount raised since Q4 2009’s $976 million. ( S
In Vivo
IN VITRO DIAGNOSTICS Mergers & Acquisitions Analytik Jena AG SIRS-Lab GMBH Life sciences firm Analytik Jena AG has acquired all of the assets of insolvent molecular diagnostics firm SIRS-Lab GMB